An aqueous orally active vaccine targeted against a RAGE/AB complex as a novel therapeutic for Alzheimer's disease

NeuroMolecular Medicine

Volumn 14, Issue 2, 2012, Pages 119-130

  Webster, Scott J ^a   Mruthinti, Shyamala ^a,b   Hill, William David ^a   Buccafusco, Jerry J ^a,b   Terry Jr , Alvin V ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Alzheimer's disease; Alzheimer's disease therapeutics; Amyloid beta; APPSWE PS1 mice; Cognition; Receptor for advanced glycation endproducts (RAGE); Vaccine

Indexed keywords

ADVANCED GLYCATION END PRODUCT; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; AMYLOID BETA PROTEIN[1-42];

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD SAMPLING; CELL PROTECTION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IMMUNOGENICITY; IN VITRO STUDY; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; TREATMENT DURATION; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ALZHEIMER VACCINES; AMYLOID BETA-PEPTIDES; ANIMALS; ANTIGEN-ANTIBODY COMPLEX; CELLS, CULTURED; HUMANS; IMMUNOGLOBULIN G; MACACA MULATTA; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; PEPTIDE FRAGMENTS; RATS; RECEPTORS, IMMUNOLOGIC;

MUS; MUS MUSCULUS; PRIMATES; RATTUS;

EID: 84861182719     PISSN: 15351084     EISSN: 15591174     Source Type: Journal    
DOI: 10.1007/s12017-012-8176-z     Document Type: Article

References (37)

1. Brookmeyer, R., Johnson, E., Ziegler-Graham, K., & Arrighi, H. M. (2007). Forecasting the global burden of Alzheimer's disease. Alzheimers & Dementia, 3(3), 186-191. (Pubitemid 46825511)
2. Bucciarelli, L. G., Wendt, T., Qu, W., Lu, Y., Lalla, E., Rong, L. L., et al. (2002). RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation, 106(22), 2827-2835. (Pubitemid 35396983)
3. Buttini, M., Masliah, E., Barbour, R., Grajeda, H., Motter, R., Johnson-Wood, K., et al. (2005). Beta-amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer's disease. Journal of Neuroscience, 25, 9096-9101. (Pubitemid 41500817)
4. Chen, Y., Yan, S. S., Colgan, J., Zhang, H. P., Luban, J., Schmidt, A. M., et al. (2004). Blockade of late stages of autoimmune diabetes by inhibition of the receptor for advanced glycation end products. Journal of Immunology, 173, 1399-1405. (Pubitemid 38924321)
5. Coors, E. A., Seybold, H., Merk, H. F., & Mahler, V. (2005). Polysorbate 80 in medical products and nonimmunologic anaphylactoid reactions. Annals of Allergy, Asthma & Immunology, 95(6), 593-599. (Pubitemid 43010488)
6. Deane, R., Yan, S. D., Submamaryan, R. K., LaRue, B., Jovanovic, S., Hogg, E., et al. (2003). RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nature Medicine, 9(7), 907-913. (Pubitemid 36889934)
7. Fang, F., Lue, L. F., Yan, S., Xu, H., Luddy, J. S., Chen, D., et al. (2010). RAGE-dependent signaling in microglia contributes to neuroinflammation, Abeta accumulation, and impaired learning/memory in a mouse model of Alzheimer's disease. The FASEB Journal, 24(4), 1043-1055.
8. Gilman, S., Koller, M., Black, R. S., Jenkins, L., Griffith, S. G., Fox, N. C., et al. (2005). Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology, 64(9), 1553-1562. (Pubitemid 40617691)
9. Herring, A., Ambreé, O., Tomm, M., Habermann, H., Sachser, N., Paulus, W., et al. (2008). Environmental enrichment enhances cellular plasticity in transgenic mice with Alzheimer-like pathology. Brain Pathology, 18, 32-39.
10. Hyman, B. T., Van Hoesen, G. W., Damasio, A. R., & Barnes, C. L. (1984). Alzheimer's disease: Cell-specific pathology isolates the hippocampal formation. Science, 225(4667), 1168-1170. (Pubitemid 14029099)
11. Lopez, O. L., Smith, G., Becker, J. T., Meltzer, C. C., & DeKosky, S. T. (2001). The psychotic phenomenon in probable Alzheimer's disease: A positron emission tomography study. Journal of Neuropsychiatry and Clinical Neurosciences, 13(1), 50-55. (Pubitemid 32151916)
12. Lue, L. F., Walker, D. G., Brachova, L., Beach, T. G., Rogers, J., Schmidt, A. M., et al. (2001). Involvement of microglial receptor for advanced glycation endproducts (RAGE) in Alzheimer's disease. Identification of a cellular activation mechanism. Experimental Neurology, 171, 29-45. (Pubitemid 32848443)
13. Marx, F., Blasko, I., Pavelka, M., & Grubeck-Loebenstein, B. (1998). The possible role of the immune system in Alzheimer's disease. Experimental Gerontology, 33, 871-881. (Pubitemid 29019341)
14. McGeer, P. L., & McGeer, E. G. (2001). Inflammation, autotoxicity and Alzheimer disease. Neurobiology of Aging, 22(799), 809.
15. McGeer, P. L., & McGeer, E. G. (2002). Local neuroinflammation and the progression of Alzheimer's disease. Journal of Neurovirology, 8, 529-538. (Pubitemid 36104718)
16. Mruthinti, S., Messing, M., & Sarkar, N. H. (1995). (OC-147) and human (H-106) monoclonal antibodies reactive with 53 kDa ovarian tumor-associated antigen. Annals of the New York Academy of Sciences, 768, 264-268. (Pubitemid 26078746)
17. Mruthinti, S., Hill, W. D., Swamy-Mruthinti, S., & Buccafusco, J. J. (2003). Relationship between the induction of RAGE cellsurface antigen and the expression of amyloid binding sites. Journal of Molecular Neuroscience, 20, 17-26.
18. Mruthinti, S., Buccafusco, J. J., Hill, W. D., Waller, J. L., Jackson, T. W., Zamrini, E. Y., et al. (2004). Autoimmunity in Alzheimer's disease: Increased levels of circulating IgGs binding A. and RAGE peptides. Neurobiology of Aging, 25, 1023-1032. (Pubitemid 38798064)
19. Mruthinti, S., Schade, R. F., Harrell, D. U., Gulati, N. K., Swamy-Mruthinti, S., Lee, G. P., et al. (2006). Autoimmunity in Alzheimer's disease as evidenced by plasma immunoreactivity against RAGE and Abeta42: Complication of diabetes. Current Alzheimer Research, 3(3), 229-235. (Pubitemid 43988136)
20. Mruthinti, S., Capito, N., Sood, A., & Buccafusco, J. J. (2007). Cytotoxicity of Abeta1-42, RAGE23-54, and an Abeta-RAGE complex in PC-12 cells. Current Alzheimer Research, 4(5), 581-586. (Pubitemid 350248397)
21. Nath, A., Hall, E., Tuzova, M., Dobbs, M., Jons, M., Anderson, C., et al. (2003). Autoantibodies to amyloid beta-peptide (Abeta) are increased in Alzheimer's disease patients and Abeta antibodies can enhance Abeta neurotoxicity: Implications for disease pathogenesis and vaccine development. Neuro Molecular Medicine, 3(1), 29-39. (Pubitemid 37070580)
22. Orgogozo, J.M., Gilman, S., Dartigues, J.F., Laurent, B., Puel, M., Kirby, L.C., et al. (2003). Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology, 61(1), 46-54. (Pubitemid 36818745)
23. Price, K.S., & Hamilton, R.G. (2007). Anaphylactoid reactions in two patients after omalizumab administration after successful longterm therapy. Allergy and Asthma Proceedings, 28(3), 313-319.
24. Pride, M., Seubert, P., Grundman, M., Hagen, M., Eldridge, J., & Black, R. S. (2008). Progress in the active immunotherapeutic approach to Alzheimer's disease: clinical investigations into AN1792-associated meningoencephalitis. Neurodegenerative Diseases, 5(3-4), 194-196. (Pubitemid 351347848)
25. Rafii, M. S., & Aisen, P. S. (2009). Recent developments in Alzheimer's disease therapeutics. BMC Medicine, 19(7), 7.
26. Raghavendra, V., Tanga, F. Y., & DeLeo, J. A. (2004). Complete Freunds adjuvant-induced peripheral inflammation evokes glial activation and proinflammatory cytokine expression in the CNS. European Journal of Neuroscience, 20(2), 467-473. (Pubitemid 38969631)
27. Ramasamy, R., Vannucci, S. J., Yan, S. S., Herold, K., Yan, S. F., & Schmidt, A. M. (2005). Advanced glycation end products and RAGE: A common thread in aging, diabetes, neurodegeneration, and inflammation. Glycobiology, 15(7), 16R.
28. Savonenko, A., Xu, G. M., Melnikova, T., Morton, J. L., Gonzales, V., Wong, M. P., et al. (2005). Episodic-like memory deficits in the APPswe/PS1dE9 mouse model of Alzheimer's disease: Relationships to beta-amyloid deposition and neurotransmitter abnormalities. Neurobiology of Diseases, 18, 602-617. (Pubitemid 40332718)
29. Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., et al. (1999). Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature, 400, 173-177. (Pubitemid 29327547)
30. Takuma, K., Fang, F., Zhang, W., Yan, S., Fukuzaki, E., Du, H., et al. (2009). RAGE-mediated signaling contributes to intraneuronal transport of amyloid-beta and neuronal dysfunction. Proceedings of the National Academy of Sciences of the USA, 106(47), 20021-20026.
31. Tanzi, R. E., Moir, R. D., & Wagner, S. L. (2004). Clearance of Alzheimer's Abeta peptide: The many roads to perdition. Neuron, 43, 605-608. (Pubitemid 39179722)
32. Trojanowski, J. Q., Duff, K., Fillit, H., Koroshetz, W., Kuret, J., Murphy, D., et al. (2008). New directions for frontotemporal dementia drug discovery. Alzheimers & Dementia, 4(2), 89-93. (Pubitemid 351373199)
33. Wilson, J. S., Mruthinti, S., Buccafusco, J. J., Schade, R. F., Mitchell, M. B., Harrell, D. U., et al. (2009). Anti-RAGE and Abeta immunoglobulin levels are related to dementia level and cognitive performance. Journals of Gerontology. Series A, Biological Sciences and Medical Sciences, 64(2), 264-271.
34. Yan, S. D., Chen, X., Fu, J., Chen, M., Zhu, H., Roher, A., et al. (1996). RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature, 382, 685-691. (Pubitemid 26282167)
35. Yan, S. D., Zhu, H., Fu, J., Yan, S. F., Roher, A., Tourtellotte, W. W., et al. (1997). Amyloid-beta peptide-receptor for advanced glycation endproduct interaction elicits neuronal expression of macrophage-colony stimulating factor: A proinflammatory pathway in Alzheimer disease. Proceedings of 67th National Academy of Science (USA), 94, 5296-5301. (Pubitemid 27214777)
36. Zhang, L., Postina, R.,&Wang, Y. (2009). Ectodomain shedding of the receptor for advanced glycation end products: A novel therapeutic target for Alzheimer's disease. Cellular and Molecular Life Sciences. Review article. doi:10.1007/s00018-009-0121-4.
37. Ziegler-Graham, K., Brookmeyer, R., Johnson, E., & Arrighi, H. M. (2008). Worldwide variation in the doubling time of Alzheimer's disease incidence rates. Alzheimers & Dementia, 4(5), 316-323.